Recombinant TNF alpha (Adalimumab Biosimilar) antibody

Catalog No. ABIN7200655

This anti-TNF alpha (Adalimumab Biosimilar) antibody is a Mouse Monoclonal antibody detecting TNF alpha (Adalimumab Biosimilar) in FACS and in vivo. Suitable for Human.

Quick Overview for Recombinant TNF alpha (Adalimumab Biosimilar) antibody (ABIN7200655)

Target: TNF alpha (Adalimumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TNF alpha (Adalimumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Clone: D2E7

Product Details anti-TNF alpha (Adalimumab Biosimilar) Antibody

Purpose: Adalimumab Biosimilar, TNF alpha Monoclonal Antibody

Specificity: The monoclonal antibody adalimumab biosimilar specifically binds to the human TNF alpha.

Characteristics: Recombinant Humanized IgG1 Monoclonal Antibody.

Purification: Protein A affinity column

Purity: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody adalimumab biosimilar was produced in the adalimumab biosimilar CHO stable cell line.

Isotype: IgG1 kappa

Application Details

Application Notes: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by adalimumab.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Preservative: Without preservative

Handling Advice: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Expiry Date: 12 months

Target Details for TNF alpha (Adalimumab Biosimilar)

Target: TNF alpha (Adalimumab Biosimilar)

Target Type: Biosimilar

Background: Adalimumab, the first fully human monoclonal antibody drug approved by FDA, binds to TNFα, inactivates TNF receptors, and downregulates the inflammatory reactions associated with a variety of autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.

Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of immune cells. As a member of a group of cytokines that stimulate the acute phase reaction, TNF is involved in systemic inflammation and able to induce fever, apoptotic cell death, cachexia, inflammation, and to inhibit tumorigenesis and viral replication and respond to sepsis via IL1 & IL6 producing cells. Dysregulation of TNF expression could have serious impact in a variety of human diseases including Alzheimer's disease, cancer, major depression and inflammatory bowel disease.